Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI376 in Relapsed/Refractory Follicular or Marginal Zone Lymphoma
CTR20192392Phase 2Completed
- Sponsor
- Incyte
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of parsaclisib in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), sponsored by Incyte. Started Feb 2020; status: completed.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on CTR20192392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192392.